Related Experiment Video
Updated: Aug 18, 2026

Single-channel Analysis and Calcium Imaging in the Podocytes of the Freshly Isolated Glomeruli
Published on: June 27, 2015
Gentamicin and sisomicin - induced renal tubular damage
Abstract:
Early signs of aminoglycoside - induced renal tubular damage were detected in 26 patients given gentamicin and 23 given sisomicin. The urinary elimination of 3 low molecular weight proteins (LMWP) - beta 2 microglobulin, retinol binding protein and lysozyme (LZM), and the urinary activity of 2 enzymes - alanine aminopeptidase and N-acetyl-beta-glucosaminidase - was measured before, during and after treatment. In gentamicin - treated patients LMWP elimination increased, especially LZM which rose markedly during treatment and returned to normal values after its end. Enzyme activities also rose while gentamicin was being given. Sisomicin produced smaller changes. As neither the mean serum creatinine nor the mean urinary elimination of transferrin were increased, glomerular function was probably not affected. However, tubular damage was detected, as shown by the LMWP output (especially LZM) and increased enzyme activity. Urinary LMWP and enzyme measurements are presented as sensitive and reliable methods to monitor early aminoglycoside - induced tubular impairment. It is suggested that the different renal toxicities of gentamicin and sisomicin are related to differences in their accumulation in the renal cortex.
Insights
Aminoglycoside antibiotics like gentamicin can cause early kidney damage. Monitoring urinary low molecular weight proteins (LMWP) and enzymes offers a sensitive method to detect this tubular impairment.
Area of Science:
- Nephrology
- Pharmacology
- Biochemistry
Background:
- Aminoglycosides are potent antibiotics used to treat severe bacterial infections.
- Nephrotoxicity is a significant concern with aminoglycoside therapy, potentially leading to kidney damage.
- Early detection of renal tubular damage is crucial for managing aminoglycoside-induced side effects.
Purpose of the Study:
- To investigate early renal tubular damage induced by gentamicin and sisomicin.
- To evaluate the utility of urinary low molecular weight proteins (LMWP) and enzyme activity as biomarkers for aminoglycoside nephrotoxicity.
- To compare the renal toxicity profiles of gentamicin and sisomicin.
Main Methods:
- Measurement of urinary excretion of beta 2 microglobulin, retinol binding protein, and lysozyme (LZM) in patients receiving gentamicin or sisomicin.
- Assay of urinary alanine aminopeptidase and N-acetyl-beta-glucosaminidase activity.
- Monitoring of serum creatinine and urinary transferrin to assess glomerular function.
Main Results:
- Increased urinary LMWP elimination, particularly lysozyme (LZM), was observed in patients treated with gentamicin.
- Elevated urinary enzyme activities (alanine aminopeptidase, N-acetyl-beta-glucosaminidase) correlated with gentamicin administration.
- Sisomicin induced less pronounced changes in urinary markers compared to gentamicin, suggesting potentially lower nephrotoxicity.
- Glomerular function remained unaffected, as indicated by stable serum creatinine and urinary transferrin levels.
Conclusions:
- Urinary LMWP and enzyme measurements are sensitive and reliable indicators of early aminoglycoside-induced renal tubular damage.
- Lysozyme (LZM) excretion is a particularly sensitive marker for gentamicin-induced tubular impairment.
- Differences in renal toxicity between gentamicin and sisomicin may be linked to their varying accumulation in the renal cortex.
More Related Videos
07:38Induction of Nephrotic Syndrome in Mice by Retrobulbar Injection of Doxorubicin and Prevention of Volume Retention by Sustained Release Aprotinin
Published on: May 6, 2018
09:22Amikacin Protection Assay for Quantification and Visualization of Escherichia coli Cell Invasion
Published on: July 3, 2026
Related Concept Videos
Drugs that Destabilize Microtubules
Drug Elimination by Renal Route: Tubular Reabsorption
Drug Elimination by Renal Route: Tubular Secretion
Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations
Acute Kidney Injury II: Pathophysiology
Acute Kidney Injury IV: Diagnostic Studies and Prevention